blog

As a leading API/intermediate manufacturer, we showcase advanced synthesis tech and regulatory-ready solutions at CPHI 2025. Booth No.: W2G30

Expert analysis of API synthesis complexities: route selection trade-offs, scale-up challenges, impurity control tactics, and green chemistry innovations. Includes industrial case studies on yield optimization and troubleshooting.

This guide reveals why your Pharmaceutical Ingredient List is vital for compliance and innovation. Learn sourcing strategies, quality benchmarks, and 2024 API trend（Attached API list）

Analyzes molecular, manufacturing, and clinical distinctions between orforglipron and GLP-1 Receptor Agonists. Covers stability, scalability, and sourcing strategies for metabolic drug developers.

Analyzes critical quality markers for premium PQQ supplements: disodium salt bioavailability, stability assurance, and manufacturing red flags. Includes GMP production standards.

Analyzes nicotinamide riboside chloride’s NAD+ boosting mechanism, therapeutic uses, production challenges (purity, stability), and key supplier selection criteria for supplement developers. Includes GMP manufacturing insights.

Green chemistry revolutionizes pharma API production by slashing waste (E-Factor), replacing toxic solvents, and cutting energy use. Tianming demonstrates eco-efficient catalytic innovation, water-based systems, and closed-loop recycling for sustainable drug manufacturing.

Tianming Pharma pioneers Orforglipron intermediates for oral GLP-1 drugs, enabling cold chain-free obesity/diabetes therapies. Backed by China’s policy & scaled cGMP production, we power global partners to reshape markets with innovation.

Analyzing the evolving API market: covers geographic shifts, technical challenges like continuous processing, and critical supplier selection criteria. Includes regulatory updates and specialty API capabilities.

Analyzing the avibactam sodium API market: Covers synthesis innovations, regulatory hurdles, and supplier selection criteria for β-lactamase inhibitor production. Includes technical benchmarks for stability and combination therapies.